<DOC>
	<DOC>NCT01900899</DOC>
	<brief_summary>The purpose of this study is to evaluate the long-term antibody persistence as well as safety of GSK Biologicals' MenACWY-TT vaccine versus Meningitec up to 6 years after booster vaccination administered in healthy 5 year old children in the study MENACWY-TT-048 EXT: 039 Y2, 3, 4, 5 (NCT00955682), who were primed with the same vaccine in the study MENACWY-TT-039 (NCT00474266) at 12 through 23 months of age.</brief_summary>
	<brief_title>Study to Evaluate the Persistence of Antibodies After GlaxoSmithKline (GSK) Biologicals' Meningococcal Vaccine (GSK134612) in Healthy Children</brief_title>
	<detailed_description>The subjects in this study will be allocated to the same groups as in study MENACWY-TT-048 EXT: 039 Y2, 3, 4, 5 (NCT00955682). No vaccine will be administered during this long-term persistence study.</detailed_description>
	<mesh_term>Meningococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<criteria>All subjects must satisfy ALL the following criteria at study entry: Subjects' parent(s)/Legally Acceptable Representative(s) [LAR(s)] who, in the opinion of the investigator, can and will comply with the requirements of the protocol. A male or female who has received primary and booster vaccination with the MenACWYTT or Meningitec vaccines in studies MENACWYTT039 (109670) and MENACWYTT048 EXT: 039 Y2, 3, 4, 5 (112036), respectively. Written informed consent obtained from the parent(s)/LAR(s) of the subject. Healthy subjects as established by medical history and clinical examination before entering into the study. The following criteria should be checked at the time of study entry. If ANY exclusion criterion applies, the subject must not be included in the study: Child in care. History of meningococcal disease. Administration of a meningococcal polysaccharide or a meningococcal polysaccharide conjugate vaccine outside of studies MENACWYTT039 (109670) and MENACWYTT048 EXT: 039 Y2, 3, 4, 5 (112036). Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination. Bleeding disorders, such as thrombocytopenia, or subjects on anticoagulant therapy.</criteria>
	<gender>All</gender>
	<minimum_age>7 Years</minimum_age>
	<maximum_age>12 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Healthy</keyword>
	<keyword>Immunogenicity</keyword>
	<keyword>Children</keyword>
	<keyword>Neisseria meningitidis</keyword>
	<keyword>Long-term antibody persistence</keyword>
	<keyword>Safety</keyword>
	<keyword>Serogroups A, C, W-135, and Y</keyword>
</DOC>